Literature DB >> 2828478

The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus.

R Grunow1, S Jahn, T Porstmann, S S Kiessig, H Steinkellner, F Steindl, D Mattanovich, L Gürtler, F Deinhardt, H Katinger.   

Abstract

This paper describes the construction of a new heteromyeloma cell line designated CB-F7. The cell line was derived from xenogeneic somatic cell hybridization between normal human B lymphocytes and the murine HAT-sensitive P3X63Ag8/653 cell line. CB-F7 cells were characterized by rapid cell growth (doubling time about 16 h) and high cloning efficiencies in culture medium supplemented with 10% or 5% fetal calf serum, respectively. The karyotype of the cells consists of about 75-78 chromosomes as well as two chromosomal fragments. Fusions of the cells with human peripheral blood cells resulted in approximately 2-6 clones per 10(5) seeded lymphocytes. Furthermore, the cells are ouabain resistant and therefore suitable for fusions with EBV-transformed lymphoblastoid cell lines. Using CB-F7 as the parental cell line a number of specific human mAb producing hybrids were established. For the first time, we describe here the generation of hybrids secreting human monoclonal antibodies to human immunodeficiency virus (HIV). Two monoclonal antibodies of IgG type and one of IgM type reacted with the major core protein p25 and one IgG antibody reacted with the transmembrane protein gp41.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828478     DOI: 10.1016/0022-1759(88)90206-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  29 in total

1.  Development of human monoclonal antibodies: A review.

Authors:  T Lindl
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal antibody specific to HIV-1-gp41.

Authors:  M Felgenhauer; J Kohl; F Rüker
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

3.  Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.

Authors:  V Boyer; H Broly; S Souche; P Madaule; J Rossier; D Zagury; C Desgranges
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

4.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Nucleotide sequence of cDNA encoding the BYMV coat protein gene.

Authors:  K Boye; P E Jensen; B M Stummann; K W Henningsen
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

Review 6.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

7.  Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Authors:  Mei-Yun Zhang; Vidita Choudhry; Igor A Sidorov; Vladimir Tenev; Bang K Vu; Anil Choudhary; Hong Lu; Gabriela M Stiegler; Hermann W D Katinger; Shibo Jiang; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2006-10-16       Impact factor: 2.303

8.  Characterization of monoclonal islet cell reactive autoantibodies from the diabetic biobreeding (BB/OK) rat.

Authors:  B Ziegler; S Witt; K D Kohnert; M Schlosser; P Augstein; D Michaelis; I Klöting; M Ziegler
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

9.  Production of human monoclonal antibodies to myeloperoxidase.

Authors:  M R Ehrenstein; B Leaker; D Isenberg; G Cambridge
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

10.  Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope.

Authors:  M Ohlin; J Hinkula; P A Broliden; R Grunow; C A Borrebaeck; B Wahren
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.